We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+3.23%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$472B
AUM Growth
+$3.53B
Cap. Flow
-$5.2B
Cap. Flow %
-1.1%
Top 10 Hldgs %
16.24%
Holding
2,596
New
95
Increased
1,094
Reduced
954
Closed
84

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.2B
2
AGN
Allergan plc
AGN
+$1.03B
3
GILD icon
Gilead Sciences
GILD
+$917M
4
PFE icon
Pfizer
PFE
+$901M
5
NKE icon
Nike
NKE
+$872M

Sector Composition

Rank Sector Weight
1 Healthcare 19.88%
2 Consumer Discretionary 14.86%
3 Financials 14.2%
4 Technology 12.51%
5 Industrials 9.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VOXX
2476
DELISTED
VOXX International Corporation Class A
VOXX
$40K ﹤0.01%
14,364
-100
-0.7% -$372
ASTC icon
2477
Astrotech Corp
ASTC
$17.5M
$38K ﹤0.01%
150
-1
-0.7% -$274
FPP
2478
DELISTED
FieldPoint Petroleum Corporation
FPP
$38K ﹤0.01%
59,200
GYRE icon
2479
Gyre Therapeutics
GYRE
$706M
$37K ﹤0.01%
219
NAVB
2480
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$37K ﹤0.01%
3,500
-20
-0.6% -$393
ACW
2481
DELISTED
Accuride Corp
ACW
$35K ﹤0.01%
28,100
EVRI
2482
DELISTED
Everi Holdings
EVRI
$33K ﹤0.01%
28,700
-200
-0.7% -$333
STLY
2483
DELISTED
Stanley Furniture Co Inc
STLY
$32K ﹤0.01%
12,900
OCC icon
2484
Optical Cable Corp
OCC
$149M
$29K ﹤0.01%
12,869
FNJN
2485
DELISTED
Finjan Holdings, Inc.
FNJN
$28K ﹤0.01%
15,450
+1,300
+9% +$1.84K
RXII
2486
DELISTED
GALENA BIOPHARMA INC COM
RXII
$28K ﹤0.01%
60,900
+1,000
+2% +$460
LPTH icon
2487
Lightpath Technologies
LPTH
$862M
$26K ﹤0.01%
+15,000
New +$27.8K
PRSO icon
2488
Peraso
PRSO
$10.4M
$21K ﹤0.01%
6
BEBE
2489
DELISTED
Bebe Stores Inc
BEBE
$21K ﹤0.01%
4,210
FTEK icon
2490
Fuel Tech
FTEK
$45.9M
$20K ﹤0.01%
13,700
BIOL
2491
DELISTED
Biolase, Inc.
BIOL
$20K ﹤0.01%
1
CVO
2492
DELISTED
Cenevo, Inc.
CVO
$20K ﹤0.01%
3,063
BONT
2493
DELISTED
Bon-Ton Stores Inc/The
BONT
$20K ﹤0.01%
14,200
ZN
2494
DELISTED
Zion Oil & Gas, Inc.
ZN
$16K ﹤0.01%
+11,600
New +$19.1K
HNR
2495
DELISTED
Harvest Natural Resources
HNR
$12K ﹤0.01%
3,529
GNK icon
2496
Genco Shipping & Trading
GNK
$1.1B
$10K ﹤0.01%
1,799
KEG
2497
DELISTED
KEY ENERGY SERVICES INC
KEG
$4K ﹤0.01%
16,400
FPP.WS
2498
DELISTED
FieldPoint Petroleum Corporation Common Stock Purchase Warrants
FPP.WS
$1K ﹤0.01%
46,200
ACNT icon
2499
Ascent Industries
ACNT
$133M
-180,463
Closed -$1.43M
BRFS
2500
DELISTED
BRF SA
BRFS
-5,750,603
Closed -$81.8M

Similar funds

T. Rowe Price Associates's Q2 2016 Portfolio in Review

As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
  • T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
  • T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
  • T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
  • T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
  • T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
  • T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.